All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-CQ1691 | Anti-OSBP (5A3) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 5A3 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ1692 | Anti-OSBP (1A4) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 1A4 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ1693 | Anti-OSBP (CBXO-0355) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBXO-0355 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ1694 | Anti-OSBP (1F2) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 1F2 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ5115 | Anti-OSBP (5A3) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 5A3 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ5116 | Anti-OSBP (1A4) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 1A4 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ5117 | Anti-OSBP (CBXO-0355) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXO-0355 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ5118 | Anti-OSBP (1F2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 1F2 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION